Purpose: We quantified the effects of Florida's prescription drug monitoring program and pill mill law on high-risk patients.
The epidemic is so far-reaching that drug overdoses are now 1 of the leading causes of death among Americans under 50 years of age, 10, 11 despite evidence suggesting the prevalence of pain has not substantially changed. 12, 13 Many policies have been developed to address opioid-related morbidity and mortality. [14] [15] [16] [17] [18] In the United States, states have increasingly implemented prescription drug monitoring programs (PDMPs) and "pill mill" laws. 16, 17, 19, 20 Prescription drug monitoring programs are databases that aggregate information about individuals' controlled substance prescribing history; they can be queried by health-care providers and certain stakeholders. 17, 21, 22 In contrast, pill mill laws establish regulatory oversight of pain management clinics-such as creating penalties for those who do not comply with state registration, ownership requirements, or limitations on physician dispensing-to mitigate problematic prescribing practices such as cash-for-pill exchanges. 23 Many studies suggest that these policies can reduce prescription opioid utilization 16, 20, 24, 25 and deaths. 26 However, some studies fail to identify such impact. [27] [28] [29] [30] Primarily focused on Florida given its role as an epicenter of nonmedical prescription opioid use, our work found that Florida's PDMP and pill mill law were associated with modest declines in overall opioid sales 20 and that these declines were concentrated among the highest prescribing physicians. 25 Previous studies do not answer how policies may affect patients at differing levels of risk of addiction and death. Not all opioid users have identical likelihood of experiencing morbidity or mortality, and clinical characteristics of patients, such as their combined use of benzodiazepines and opioids, or long-term high-dose opioid use, have been consistently associated with a substantially elevated risk. [31] [32] [33] [34] [35] In this study, we sought to (1) describe the characteristics of high-risk patients and their counterparts in Florida and (2) compare opioid utilization in Florida with Georgia to quantify the effect of Florida's PDMP and pill mill law on their opioid utilization by patients' risk status.
2 | METHODS
| Data
We used QuintilesIMS LifeLink Longitudinal Prescription (LRx) data, which consists of anonymized, individual-level prescription drug dispensing data. The database includes payer, patient, and prescriber information derived from approximately 75% of all retail prescription transactions in the United States. Each transaction record includes the National Drug Code, quantity dispensed, days supplied, quantity dispensed, zip code of the dispensing pharmacy, encrypted prescriber identifiers, patient sex, and date of birth.
| Time segments and group derivation
We included a 12-month pre-and postintervention observation We defined 3 types of patients at elevated risks of adverse events. 36 First, we defined "concomitant users" as patients filling more than 30 days (not necessarily continuous) of concomitant opioids and benzodiazepines in a year. The coadministration of benzodiazepines and opioids may lead to more adverse events, with benzodiazepines associated with~30% of overdose deaths involving prescription opioids. 34, 35 Second, we defined "chronic users" as those consuming more than 100 MMEs per day for more than 90 consecutive days, as there is a strong dose-response association between the opioid dose and the overdose death risk. 31, 33 Finally, we defined "opioid shoppers" as patients visiting ˃3 pharmacies and ˃3 prescribers to acquire opioids during any 90-day period because using multiple concurrent prescribers and pharmacies is related to a 600% increase in opioid overdose. 37, 38 Patients not meeting the criterion were considered "low-risk" by the definition. These 3 groups were not mutually exclusive. Total prescriptions were not used as a measure of high-risk as they do not account for product or dose.
| Outcomes
We examined 4 outcomes, derived on a monthly basis and summarized by risk group and state. First, we calculated the average MME per transaction. Risk of opioid-related morbidity and mortality increases
KEY POINTS
• Among 1.1 million patients filling a prescription opioid in Florida prior to policy implementation, 6.6% were concomitant users, 2.0% were chronic users, and 0.5%
were opioid shoppers.
• The concentration of total opioid prescriptions among high-risk patients decreased by approximately 17%
from the prepolicy to the postpolicy period.
• Compared with Georgia, Florida's prescription drug monitoring program and pill mill law were associated with large relative reductions in prescription opioid utilization among 3 high-risk opioid groups.
• There were generally no statistically significant policy effects on nonhigh-risk patients.
as MME per transaction increases. 39 Second, we computed total opioid volume across all prescriptions by using MMEs. This measure standardizes opioid prescriptions by accounting for differences in molecules, quantity, and strength of doses. 35, 40 Third, we quantified average days supplied per transaction given many opioids are ultimately diverted. 41, 42 Fourth, we examined the total number of opioid prescriptions dispensed.
We also examined the overlap of 3 high-risk groups (concomitant users, chronic users, and opioid shoppers) and the degree to which total opioid volume was concentrated within these groups. In addition,
we compared the prevalence of 3 high-risk groups between 2 states.
| Analysis
We first described the characteristics of high-risk patients, including age, sex, prevalence, and overlap with other high-risk groups; persistence from the pre-to postperiod; and chronic disease score. The chronic disease score, using pharmacy claims only, is a validated measure of morbidity and has been linked to patient's health status, expenditures, and death. 43, 44 We used a χ 2 test to examine whether being a high-risk patient by 1 definition in the preintervention period was more likely to (1) be a high-risk patient by another definition in the preintervention period and (2) be a high-risk patient by all 3 definitions in the postintervention period.
We used a comparative interrupted time series approach to quantify the impact of Florida's laws on our outcomes while accounting for secular trends as well as the autocorrelated nature of the data. 20, 25, [45] [46] [47] We used Georgia as a control state because of its geographical proximity, the absence of similar policy implementation during the study period, and its similarity in baseline opioid utilization trends (of note, Georgia's PDMP became operational in 2013).
Our unit of analysis was a monthly measure derived by aggregating all of the transactions associated with a specific group in a given state during that month. The R 2 was higher than 0.80 across all models, a reflection of large sample sizes and little variation in the outcomes of interest over time.
All analyses were performed by using SAS version 9.4 (proc autoreg command with nlag function).
3 | RESULTS
| Characteristics of high-risk patients
Approximately 7% (6.6%) of the 1.13 million Florida individuals in the prepolicy period were concomitant users, 2.0% were chronic users, and 0.5% were opioid shoppers (Table 1 ). Among 0.54 million Georgia individuals, the prevalence was lower at 4.4%, 1.2%, and 0.4%, respectively. More than three-fifths of concomitant users (64.8%) and opioid shoppers (60.4%) were female, while slightly more chronic users (51%)
were male. Concomitant users were the oldest (mean age: 54.4 years), while chronic users were slightly younger (50.8 years) and opioid shoppers were the youngest (41.9 years).
| Opioid concentration and prevalence of highrisk patients
The concentration of total opioid prescriptions among high-risk patients decreased by approximately 17% from the prepolicy to the postpolicy period (Table 1) . For example, the proportion of opioid prescriptions accounted for by high-risk patients ranged from 40.2% among chronic users to 3.3% among opioid shoppers in the prepolicy period; these numbers decreased to 33.2% and 2.7% in the postpolicy period. In the prepolicy period, the concentration of total opioid volume within high-risk patients was somewhat lower, ranging from 23.3% (chronic users) to 2.4% (opioid shoppers); this also declined following policy implementation, ranging from 19.4% to 1.8%.
The overlap across the 3 high-risk groups was low; for example, the highest was 45% of chronic users being concomitant users. In addi- 3.4 | Observed versus predicted outcomes without policy implementation Table 3 shows the difference between the observed and the predicted outcomes had Florida's policies not been implemented. There was a greater difference between the observed and predicted outcomes during the second 6 months after the policy changes than during the first 6 months. For example, during the second 6 months, the observed total opioid volume was 34.9% less and 6.2% more than the predicted values among concomitant and nonconcomitant users, respectively.
| Effect of policy changes by types of patient risk
We estimate that at 1 year, the policies were associated with a 25% reduction in opioid volume among concomitant users, a 40.7% reduction among chronic users, and a 63.0% reduction among opioid shoppers; they were also associated with a 16.2% reduction in opioid prescriptions among concomitant users, a 24.7% reduction among chronic users, and a 42.4% reduction among opioid shoppers. Smaller reductions (eg, a 0.5% reduction among nonopioid shoppers on opioid prescriptions) or sometimes increases (eg, a 12.9% increase among chronic users on total opioid volume) were observed to be associated with the policies at 1 year among nonhigh-risk patients (Online Appendix 6).
4 | DISCUSSION Among 1.1 million patients filling a prescription opioid in Florida prior to policy implementation, 6.6% were concomitant users, 2.0% were chronic users, and 0.5% were opioid shoppers; the prevalence of these 3 high-risk groups was lower in Georgia. Across all 3 high-risk groups, these policies were associated with statistically significant comparative reductions in monthly trends of morphine equivalent dose, total opioid volume, and number of opioid prescriptions. In general, no statistically significant effects on nonhigh-risk patients were observed.
In so far as Florida's policies were designed to target those at greatest risk of opioid-related adverse events, our study suggests that the policies had their intended effect. However, the impacts seemed to be larger among high-risk patients than high-risk prescribers. For example, about 80% of high-risk prescribers remained so following policy implementation while at most 60% of high-risk patients persisted. Similarly, we estimate larger policy effects among high-risk patients than high-risk prescribers at 1 year as well; for example, we estimate a 25% to 70% reduction in total opioid volume among highrisk patients compared with a 13.5% reduction among high-risk prescribers. 25 Further study is necessary to evaluate these differential effects.
Prescription drug monitoring programs and pill mill laws are rapidly evolving state-level policies to address prescription opioid abuse and diversion. Prescription drug monitoring programs have been implemented in all but 1 state, representing nearly complete policy diffusion, with particularly rapid uptake during the last 15 years. Because PDMPs vary extensively across states, they present a natural policy-making experiment, for which rigorous evaluation has only recently begun. 16, 20, 25, 26, 29 For example, states house PDMPs in different agencies (eg, health department and pharmacy board), require PDMPs to capture information about different drug schedules, and vary in the extent to which law enforcement officials can access their data. 48, 49 One of the more controversial-and heterogeneous-aspects of 
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